AstraZeneca PLC Stock price

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 16:35:12 01/03/2024 GMT 5-day change 1st Jan Change
10,080 GBX +0.97% Intraday chart for AstraZeneca PLC -1.37% -4.91%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 51B 4,032B Sales 2025 * 54.6B 4,316B Capitalization 197B 15,608B
Net income 2024 * 8.76B 693B Net income 2025 * 10.26B 811B EV / Sales 2024 * 4.23 x
Net Debt 2024 * 18.4B 1,455B Net Debt 2025 * 12.34B 976B EV / Sales 2025 * 3.84 x
P/E ratio 2024 *
22.9 x
P/E ratio 2025 *
19.4 x
Employees 89,900
Yield 2024 *
2.43%
Yield 2025 *
2.55%
Free-Float 96.46%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.97%
1 week-1.37%
Current month+0.97%
1 month-2.70%
3 months-1.16%
6 months-5.79%
Current year-4.91%
More quotes
1 week
9 982.00
Extreme 9982.0017
10 360.00
1 month
9 461.00
Extreme 9461
10 652.00
Current year
9 461.00
Extreme 9461
11 022.00
1 year
9 461.00
Extreme 9461
12 392.00
3 years
6 761.00
Extreme 6761
12 392.00
5 years
5 626.00
Extreme 5626
12 392.00
10 years
3 680.00
Extreme 3680
12 392.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 30/09/12
Director of Finance/CFO 50 31/07/21
Chief Tech/Sci/R&D Officer 56 31/12/19
Members of the board TitleAgeSince
Director/Board Member 65 30/09/17
Corporate Officer/Principal 59 31/01/13
Director/Board Member 63 26/04/17
More insiders
Date Price Change Volume
01/03/24 10,080 +0.97% 2,743,748
29/02/24 9,983 -1.94% 4,557,962
28/02/24 10,180 -1.43% 2,604,519
27/02/24 10,328 +0.72% 6,762,882
26/02/24 10,254 +0.33% 5,309,043

Delayed Quote London S.E., March 01, 2024 at 04:35 pm

More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).
Calendar
02/03/2024 - Roadshow
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
127.4 USD
Average target price
162.2 USD
Spread / Average Target
+27.32%
Consensus
  1. Stock
  2. Equities
  3. Stock AstraZeneca PLC - London S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW